Hepatitis Monthly

Published by: Kowsar

Manipulation of Regulatory Cells’ Responses to Treatments for Chronic Hepatitis B Virus Infection

Soheil Tavakolpour 1 , Seyed Moayed Alavian 1 , * and Shahnaz Sali 2
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqyiatallah University of Medical Sciences, Tehran, IR Iran
2 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: 16 (6); e58751
  • Published Online: May 25, 2016
  • Article Type: Research Article
  • Received: March 17, 2016
  • Revised: April 14, 2016
  • Accepted: April 20, 2016
  • DOI: 10.5812/hepatmon.37927

To Cite: Tavakolpour S, Alavian S M, Sali S. Manipulation of Regulatory Cells’ Responses to Treatments for Chronic Hepatitis B Virus Infection, Hepat Mon. Online ahead of Print ; 16(6):e58751. doi: 10.5812/hepatmon.37927.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. De Clercq E, Ferir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses. 2010; 2(6): 1279-305[DOI][PubMed]
  • 2. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat. 2009; 16(3): 149-55[DOI][PubMed]
  • 3. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003; 77(1): 68-76[PubMed]
  • 4. Xue-Song L, Cheng-Zhong L, Ying Z, Mo-Bin W. Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection. BMC Gastroenterol. 2012; 12: 43[DOI][PubMed]
  • 5. Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012; 56(8): 4277-88[DOI][PubMed]
  • 6. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343(6176): 1221-8[DOI][PubMed]
  • 7. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012; 122(2): 529-37[DOI][PubMed]
  • 8. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012; 61(12): 1754-64[DOI][PubMed]
  • 9. Tavakolpour S. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus. Dermatol Ther. 2016; [DOI][PubMed]
  • 10. Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine. 2016; 77: 189-95[DOI][PubMed]
  • 11. Tavakolpour S. Interleukin 21 as a new possible player in pemphigus: Is it a suitable target? Int Immunopharmacol. 2016; 34: 139-45[DOI][PubMed]
  • 12. Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, et al. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010; 2010: 143026[DOI][PubMed]
  • 13. Tavakolpour S. Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients. Immunol Lett. 2016; 171: 70-1[DOI][PubMed]
  • 14. Wang Q, Zhou J, Zhang B, Tian Z, Tang J, Zheng Y, et al. Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis. PLoS Pathog. 2013; 9(6): 1003410[DOI][PubMed]
  • 15. Kamimura D, Bevan MJ. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med. 2007; 204(8): 1803-12[DOI][PubMed]
  • 16. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion. PLoS Pathog. 2013; 9(7): 1003490[DOI][PubMed]
  • 17. Li X, Kong H, Tian L, Zhu Q, Wang Y, Dong Y, et al. Changes of costimulatory molecule CD28 on circulating CD8+ T cells correlate with disease pathogenesis of chronic hepatitis B. Biomed Res Int. 2014; 2014: 423181[DOI][PubMed]
  • 18. Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007; 15(4): 143-6[DOI][PubMed]
  • 19. Xiang XG, Xie Q. IL-35: a potential therapeutic target for controlling hepatitis B virus infection. J Dig Dis. 2015; 16(1): 1-6[DOI][PubMed]
  • 20. Khorramdelazad H, Hassanshahi G, Nasiri Ahmadabadi B, Kazemi Arababadi M. High Serum Levels of TGF-beta in Iranians With Chronic HBV Infection. Hepat Mon. 2012; 12(11): 7581[DOI][PubMed]
  • 21. Karimi-Googheri M, Daneshvar H, Nosratabadi R, Zare-Bidaki M, Hassanshahi G, Ebrahim M, et al. Important roles played by TGF-beta in hepatitis B infection. J Med Virol. 2014; 86(1): 102-8[DOI][PubMed]
  • 22. Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 2015; 6: 1694[DOI][PubMed]
  • 23. Motavaf M, Safari S, Alavian SM. Interleukin 18 gene promoter polymorphisms and susceptibility to chronic hepatitis B infection: a review study. Hepat Mon. 2014; 14(7): 19879[DOI][PubMed]
  • 24. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010; 58(4): 258-66[DOI][PubMed]
  • 25. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut. 2009; 58(7): 974-82[DOI][PubMed]
  • 26. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010; 184(1): 287-95[DOI][PubMed]
  • 27. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005; 41(4): 771-8[DOI][PubMed]
  • 28. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000; 32(5): 1117-24[DOI][PubMed]
  • 29. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology. 2008; 123(1): 57-65[DOI][PubMed]
  • 30. Aalaei-Andabili SH, Alavian SM. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine. 2012; 30(38): 5595-602[DOI][PubMed]
  • 31. Park Y, Park Y, Han KH, Kim HS. Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy. J Clin Lab Anal. 2011; 25(6): 414-21[DOI][PubMed]
  • 32. Zhou Y, Zhang H, Li Y. IL-35 expression in peripheral blood CD4(+) T cells from chronic hepatitis B virus-infected patients directly correlates with virus load. Cytokine. 2015; 73(1): 169-75[DOI][PubMed]
  • 33. Tulek N, Saglam SK, Saglam M, Turkyilmaz R, Yildiz M. Soluble interleukin-2 receptor and interleukin-10 levels in patients with chronic hepatitis B infection. Hepatogastroenterology. 2000; 47(33): 828-31[PubMed]
  • 34. Zhang F, Yao S, Zhang M, Yuan J, Chen X, Zhou B. Roles of circulating soluble interleukin (IL)-6 receptor and IL-6 receptor expression on CD4+ T cells in patients with chronic hepatitis B. Int J Infect Dis. 2011; 15(4): 267-71[DOI][PubMed]
  • 35. Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol. 2013; 8: 40[DOI][PubMed]
  • 36. Marchant A, Goldman M. T cell-mediated immune responses in human newborns: ready to learn? Clin Exp Immunol. 2005; 141(1): 10-8[DOI][PubMed]
  • 37. Shrivastava S, TrehanPati N, Patra S, Kottilil S, Pande C, Trivedi SS, et al. Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns. J Viral Hepat. 2013; 20(8): 582-91[DOI][PubMed]
  • 38. Gong Y, Zhao C, Zhao P, Wang M, Zhou G, Han F, et al. Role of IL-10-Producing Regulatory B Cells in Chronic Hepatitis B Virus Infection. Dig Dis Sci. 2015; 60(5): 1308-14[DOI][PubMed]
  • 39. Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 2012; 189(8): 3925-35[DOI][PubMed]
  • 40. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010; 11(12): 1093-101[DOI][PubMed]
  • 41. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014; 507(7492): 366-70[DOI][PubMed]
  • 42. Strauss L, Bergmann C, Whiteside TL. IL-15 administration to human CD4+ T cells leads to expansion of CD4+ CD25-cells but to a decrease of CD4+ CD25highFoxp3+ T cells via apoptosis. J Immunol. 2007; 178: 147
  • 43. Lu J, Giuntoli RL, Omiya R, Kobayashi H, Kennedy R, Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002; 8(12): 3877-84[PubMed]
  • 44. Chen YM, Ting CC, Peng JW, Yang WK, Yang KY, Tsai CM, et al. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2. J Interferon Cytokine Res. 2000; 20(1): 31-9[DOI][PubMed]
  • 45. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013; 13: 5[PubMed]
  • 46. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008; 13 Suppl 4: 2-9[DOI][PubMed]
  • 47. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4): 252-64[DOI][PubMed]
  • 48. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11): 3887-95[PubMed]
  • 49. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008; 45(4): 963-70[DOI][PubMed]
  • 50. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology. 2008; 48(3): 759-69[DOI][PubMed]
  • 51. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010; 138(2): 682-93[DOI][PubMed]
  • 52. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008; 205(12): 2763-79[DOI][PubMed]
  • 53. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207(10): 2175-86[DOI][PubMed]
  • 54. Liu Y, Gao LF, Liang XH, Ma CH. Role of Tim-3 in hepatitis B virus infection: An overview. World J Gastroenterol. 2016; 22(7): 2294-303[DOI][PubMed]
  • 55. Ju Y, Hou N, Zhang XN, Zhao D, Liu Y, Wang JJ, et al. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol. 2009; 6(1): 35-43[DOI][PubMed]
  • 56. Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y, et al. Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. Eur J Immunol. 2012; 42(5): 1180-91[DOI][PubMed]
  • 57. Tavakolpour S. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors Clin Investig. 2016; 3(1): 1173
  • 58. Tavakolpour S. The new insight into management of hepatitis B virus patients with flare. Immunol Lett. 2016; [DOI][PubMed]
  • 59. Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review. Hepat Mon. 2016; 16(4)
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments